$NTRA
Natera, Inc.

2023 Q4 Form 10-Q Financial Statement

#000155837023018379 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $311.1M $268.3M
YoY Change 43.2% 27.38%
Cost Of Revenue $151.2M $147.3M
YoY Change 18.82% 26.42%
Gross Profit $159.9M $121.0M
YoY Change 77.7% 28.55%
Gross Profit Margin 51.38% 45.1%
Selling, General & Admin $161.4M $154.7M
YoY Change 12.24% 4.79%
% of Gross Profit 100.98% 127.89%
Research & Development $82.96M $77.24M
YoY Change -5.63% 17.9%
% of Gross Profit 51.9% 63.83%
Depreciation & Amortization $6.911M $6.990M
YoY Change 75.85% 35.97%
% of Gross Profit 4.32% 5.78%
Operating Expenses $244.4M $232.0M
YoY Change 5.46% 8.82%
Operating Profit -$84.54M -$111.0M
YoY Change -40.37% -6.78%
Interest Expense $6.696M $3.252M
YoY Change -343.31% 39.57%
% of Operating Profit
Other Income/Expense, Net $5.400M
YoY Change 6106.9%
Pretax Income -$77.84M -$108.8M
YoY Change -45.24% -10.28%
Income Tax $191.0K $202.0K
% Of Pretax Income
Net Earnings -$78.03M -$109.0M
YoY Change -45.27% -10.25%
Net Earnings / Revenue -25.08% -40.64%
Basic Earnings Per Share -$0.95
Diluted Earnings Per Share -$0.65 -$0.95
COMMON SHARES
Basic Shares Outstanding 120.2M 114.6M
Diluted Shares Outstanding 115.2M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $879.0M $936.6M
YoY Change -2.15% 79.72%
Cash & Equivalents $642.1M $668.7M
Short-Term Investments $236.9M $267.8M
Other Short-Term Assets $60.52M $33.50M
YoY Change 79.49% 5.73%
Inventory $40.76M $42.08M
Prepaid Expenses
Receivables $278.3M $255.1M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.259B $1.267B
YoY Change 3.86% 52.75%
LONG-TERM ASSETS
Property, Plant & Equipment $111.2M $104.8M
YoY Change 20.29% 19.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $15.40M $16.21M
YoY Change -15.97% -10.97%
Total Long-Term Assets $183.2M $179.2M
YoY Change 0.27% -0.13%
TOTAL ASSETS
Total Short-Term Assets $1.259B $1.267B
Total Long-Term Assets $183.2M $179.2M
Total Assets $1.442B $1.447B
YoY Change 3.39% 43.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.00M $21.32M
YoY Change -51.85% -37.7%
Accrued Expenses $172.0M $156.9M
YoY Change 1.62% -0.09%
Deferred Revenue $16.61M $15.01M
YoY Change 54.14% 89.26%
Short-Term Debt $80.40M $80.40M
YoY Change 0.0% 60.48%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $307.3M $289.9M
YoY Change -1.04% 8.47%
LONG-TERM LIABILITIES
Long-Term Debt $282.9M $282.6M
YoY Change 0.46% 0.45%
Other Long-Term Liabilities $86.15M $89.30M
YoY Change -10.79% -9.68%
Total Long-Term Liabilities $369.1M $371.9M
YoY Change -2.41% -2.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $307.3M $289.9M
Total Long-Term Liabilities $369.1M $371.9M
Total Liabilities $676.4M $661.9M
YoY Change -1.79% 2.22%
SHAREHOLDERS EQUITY
Retained Earnings -$2.400B -$2.300B
YoY Change 26.32% 27.78%
Common Stock $3.146B $3.089B
YoY Change 18.05% 41.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $765.3M $784.7M
YoY Change
Total Liabilities & Shareholders Equity $1.442B $1.447B
YoY Change 3.39% 43.35%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$78.03M -$109.0M
YoY Change -45.27% -10.25%
Depreciation, Depletion And Amortization $6.911M $6.990M
YoY Change 75.85% 35.97%
Cash From Operating Activities -$58.13M -$29.55M
YoY Change -28.35% -71.1%
INVESTING ACTIVITIES
Capital Expenditures $9.532M $9.100M
YoY Change -19.4% -174.54%
Acquisitions
YoY Change
Other Investing Activities $34.20M $90.25M
YoY Change 1.34% 14.52%
Cash From Investing Activities $24.66M $81.15M
YoY Change 12.54% 21.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.845M 236.0M
YoY Change -98.54% 16842.57%
NET CHANGE
Cash From Operating Activities -58.13M -29.55M
Cash From Investing Activities 24.66M 81.15M
Cash From Financing Activities 6.845M 236.0M
Net Change In Cash -26.62M 287.6M
YoY Change -106.51% -939.59%
FREE CASH FLOW
Cash From Operating Activities -$58.13M -$29.55M
Capital Expenditures $9.532M $9.100M
Free Cash Flow -$67.66M -$38.65M
YoY Change -27.21% -57.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
118990000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
111255000
dei Entity Registrant Name
EntityRegistrantName
Natera, Inc.
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Central Index Key
EntityCentralIndexKey
0001604821
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Shell Company
EntityShellCompany
false
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.95
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.20
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115171000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97052000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113559000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96408000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y11M8D
ntra Increase Decrease Net Income Loss
IncreaseDecreaseNetIncomeLoss
-3700000
ntra Increase Decrease Net Income Loss
IncreaseDecreaseNetIncomeLoss
16500000
CY2023Q3 ntra Increase Decrease Net Income Loss
IncreaseDecreaseNetIncomeLoss
2200000
CY2022Q3 ntra Increase Decrease Net Income Loss
IncreaseDecreaseNetIncomeLoss
5900000
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Entity File Number
EntityFileNumber
001-37478
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
01-0894487
dei Entity Address Address Line1
EntityAddressAddressLine1
13011 McCallen Pass
dei Entity Address Address Line2
EntityAddressAddressLine2
Building A Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78753
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
980-9190
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
NTRA
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
120151688
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
668710000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
466091000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
267847000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
432301000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6034000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3830000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
255147000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
244385000
CY2023Q3 us-gaap Inventory Net
InventoryNet
42076000
CY2022Q4 us-gaap Inventory Net
InventoryNet
35406000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
33496000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
33634000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
1267276000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1211817000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
104830000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92453000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
58206000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
71874000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
16208000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18330000
CY2023Q3 us-gaap Assets
Assets
1446520000
CY2022Q4 us-gaap Assets
Assets
1394474000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
21321000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
31148000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
39415000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
44010000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
133740000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
144214000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
15012000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10777000
CY2023Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
80435000
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
80350000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
289923000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
310499000
CY2023Q3 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
282619000
CY2022Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
281653000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
21033000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
20001000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
68287000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
76577000
CY2023Q3 us-gaap Liabilities
Liabilities
661862000
CY2022Q4 us-gaap Liabilities
Liabilities
688730000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
118990000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
111255000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
11000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3089448000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2664730000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2299405000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1942635000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5396000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16362000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
784658000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
705744000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1446520000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1394474000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
268306000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
210637000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
771466000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
602970000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
77235000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65510000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
237714000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
228504000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
154742000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
147667000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
456877000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
444769000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
379288000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
329689000
us-gaap Costs And Expenses
CostsAndExpenses
1133175000
us-gaap Costs And Expenses
CostsAndExpenses
1002237000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-110982000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-119052000
us-gaap Operating Income Loss
OperatingIncomeLoss
-361709000
us-gaap Operating Income Loss
OperatingIncomeLoss
-399267000
CY2023Q3 us-gaap Interest Expense
InterestExpense
3252000
CY2022Q3 us-gaap Interest Expense
InterestExpense
2330000
us-gaap Interest Expense
InterestExpense
9490000
us-gaap Interest Expense
InterestExpense
6567000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5406000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
87000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
14509000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1165000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-108828000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-121295000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-356690000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-404669000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
202000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
185000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
80000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
557000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-109030000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-121480000
us-gaap Net Income Loss
NetIncomeLoss
-356770000
us-gaap Net Income Loss
NetIncomeLoss
-405226000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
3807000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-3212000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
10966000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-17322000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-105223000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-124692000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-345804000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-422548000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.95
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.20
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115171000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97052000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113559000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96408000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
444582000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1393000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
40338000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-3212000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-121480000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
361621000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
653304000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5971000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8496000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
116398000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-17322000
us-gaap Net Income Loss
NetIncomeLoss
-405226000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
361621000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
596147000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
562000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
235441000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
57731000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
3807000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-109030000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
784658000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
705744000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3501000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8674000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
19771000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
14435000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
235441000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
142896000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
10966000
us-gaap Net Income Loss
NetIncomeLoss
-356770000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
784658000
us-gaap Profit Loss
ProfitLoss
-356770000
us-gaap Profit Loss
ProfitLoss
-405226000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17186000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12772000
ntra Expensed In Process Research And Development
ExpensedInProcessResearchAndDevelopment
2679000
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
1929000
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
3971000
us-gaap Share Based Compensation
ShareBasedCompensation
142896000
us-gaap Share Based Compensation
ShareBasedCompensation
116398000
us-gaap Operating Lease Cost
OperatingLeaseCost
11011000
us-gaap Operating Lease Cost
OperatingLeaseCost
9989000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
966000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
941000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-265000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
12000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-532000
ntra Non Cash Interest Expense
NonCashInterestExpense
85000
ntra Non Cash Interest Expense
NonCashInterestExpense
100000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10762000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
114288000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6669000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
13520000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7356000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-486000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8951000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8367000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
15177000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1285000
us-gaap Operating Lease Payments
OperatingLeasePayments
8424000
us-gaap Operating Lease Payments
OperatingLeasePayments
7207000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2072000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
35422000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
5268000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-384000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-188830000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-350374000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
86947000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
214738000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
173500000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
216500000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29667000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35870000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
143833000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
308421000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3501000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5971000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
8674000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
8496000
ntra Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
235441000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
247616000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14467000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
202619000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-27486000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
466091000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84614000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
668710000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57128000
us-gaap Interest Paid Net
InterestPaidNet
6907000
us-gaap Interest Paid Net
InterestPaidNet
4008000
ntra Purchases Of Property And Equipment In Accounts Payable And Accruals
PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruals
-1168000
ntra Purchases Of Property And Equipment In Accounts Payable And Accruals
PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruals
458000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
14435000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
19771000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16397000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16362000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2287000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5396000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-19609000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5396000
us-gaap Net Income Loss
NetIncomeLoss
-356800000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2300000000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
668700000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
267800000
CY2023Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
80400000
CY2023Q3 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
20000000.0
CY2023Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
55
CY2023Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
400000
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
235800000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13144500
CY2022Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
35
CY2022Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
500000
CY2022Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
433200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The preparation of financial statements in accordance with generally accepted accounting principles (“GAAP”) in the United States requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Significant items subject to such estimates include the allowance for doubtful accounts, average selling price expected to be received from payors, the discount rate impacting the operating right-of-use assets and the associated lease liabilities, the average useful life for property and equipment, deferred revenues associated with unsatisfied performance obligations, accrued liability for potential refund requests, stock-based compensation, the fair value of options, income tax uncertainties, and the expected consideration to be received from contracts with customers. These estimates and assumptions are based on management's best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors, including contractual terms and statutory limits; however, actual results could differ from these estimates and could have an adverse effect on the Company's financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The total consideration which the Company expects to be entitled to receive from patients and insurance carriers in exchange for the Company's products is a significant estimate determined by calculating the average selling price based on the contractual pricing agreed to with each insurance carrier for each test (CPT code) performed adjusted for variable consideration related to historical percent of cases allowed, historical percent of patient responsibility collected, and historical percent of contract price collected from insurance carriers. The Company uses the expected-value approach of estimating variable consideration.  The Company also considers recent trends, past events not expected to recur, and future known changes such as anticipated contractual pricing changes or changes to insurance coverage.  For insurance carriers with similar reimbursement characteristics, the Company uses a portfolio approach to estimate the effects of variable consideration. The Company also applies a constraint to the estimated variable consideration when it assesses it is probable that a significant reversal in the amount of cumulative revenue may occur in future periods. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">When assessing the total consideration expected to be received from insurance carriers and patients, a certain percentage of revenues is further constrained for estimated refunds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Allowance for doubtful accounts</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The allowance for doubtful accounts for trade accounts receivable is based on the Company’s assessment of the collectability of accounts related to our clinics and laboratory partner customers. The Company regularly reviews the allowance by considering factors such as historical experience, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. See Note 6, <i style="font-style:italic;">Balance Sheet Components</i>, for a roll-forward of the allowance for doubtful accounts related to trade accounts receivable for the three and nine months ended September 30, 2023 and 2022. The Company currently does not have an incremental allowance for doubtful accounts against accounts receivable for insurance and patient payors due to the average selling price calculations which incorporate these risks as net receivables are recorded. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Inventory</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Inventory is recorded at the lower of cost or net realizable value, determined on a first-in, first-out basis. The Company uses judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. A write down of specifically identified unusable, obsolete, slow-moving or known unsalable inventory in the period is first recognized by using a number of factors including product expiration dates and scrapped inventory. Any write-down of inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded to cost of revenue on our consolidated statements of operations. The Company makes assumptions about future demand, market conditions and the release of new products that may supersede older products. However, if actual market conditions are less favorable than anticipated, additional inventory write-downs may be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Investments and financial instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Company classifies its investments as Level 1 or 2 within the fair value hierarchy. Fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets that the Company has the ability to access. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. The Company holds Level 2 securities which are initially valued at the transaction price and subsequently valued by a third-party service provider using inputs other than quoted prices that are observable either directly or indirectly, such as yield curve, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, broker and dealer quotes, as well as other relevant economic measures. The Company performs certain procedures to corroborate the fair value of these holdings.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Other accrued liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Company's uses estimates, judgments, and assumptions in several areas including, but not limited to, estimates of progress to date for certain contracts with vendors, liabilities related to clinical trials, payroll and related expenses, marketing liabilities, reserves associated with insurance and general overpayments, tax-related liabilities, and other operating expenses. Estimates consist of historical trends, analytical procedures, review of supporting documentation, inquiries with supply partners and vendors, and other relevant assumptions. Although the Company believes its estimates, assumptions, and judgment are reasonable, they are based upon information presently available and are subject to change.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Risk and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents, accounts receivable and investments. The Company limits its exposure to loss by placing its cash in financial institutions with high credit ratings. The Company's cash may consist of deposits held with banks that may at times exceed federally insured limits of $250,000 per customer. The Company performs evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any one institution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The Company performs evaluations of financial conditions for insurance carriers, patients, clinics and laboratory partners and generally does not require collateral to support credit sales. For the three and nine months ended September 30, 2023, and 2022, there were no payors or customers exceeding 10% of total revenues on an individual basis. As of September 30, 2023 and December 31, 2022, there were no payors or customers with an outstanding balance exceeding 10% of net accounts receivable. </p>
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9203000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-19609000
CY2023Q3 ntra Increase Decrease Revenues
IncreaseDecreaseRevenues
2200000
CY2022Q3 ntra Increase Decrease Revenues
IncreaseDecreaseRevenues
5900000
CY2023Q3 ntra Increase Decrease Net Income Loss Per Share
IncreaseDecreaseNetIncomeLossPerShare
0.02
CY2022Q3 ntra Increase Decrease Net Income Loss Per Share
IncreaseDecreaseNetIncomeLossPerShare
0.06
ntra Increase Decrease Revenues
IncreaseDecreaseRevenues
-3700000
ntra Increase Decrease Net Income Loss Per Share
IncreaseDecreaseNetIncomeLossPerShare
-0.03
ntra Increase Decrease Revenues
IncreaseDecreaseRevenues
16500000
ntra Increase Decrease Net Income Loss Per Share
IncreaseDecreaseNetIncomeLossPerShare
0.17
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
268306000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
210637000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
771466000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
602970000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
268306000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
210637000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
771466000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
602970000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
255147000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
244385000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
15012000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10777000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
21033000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
20001000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36045000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30778000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30778000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
28722000
ntra Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
24553000
ntra Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
20268000
ntra Contract With Customer Liability Reclassification Unbilled Revenues Previously Deferred
ContractWithCustomerLiabilityReclassificationUnbilledRevenuesPreviouslyDeferred
337000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-9610000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-7877000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-9676000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-12439000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36045000
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
28337000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-9600000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
941687000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5130000
CY2023Q3 ntra Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
936557000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
914494000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
16103000
CY2022Q4 ntra Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
898392000
CY2023Q3 ntra Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
936557000
CY2022Q4 ntra Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
898392000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
38
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
267847000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
5130000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
242845000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
239773000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
30132000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
28074000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
272977000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
267847000
CY2023Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
5580000
CY2022Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
3561000
CY2023Q3 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-454000
CY2022Q3 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-1115000
CY2023Q3 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6034000
CY2022Q3 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
4676000
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
3830000
CY2021Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
2429000
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-2204000
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-2615000
us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
368000
CY2023Q3 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6034000
CY2022Q3 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
4676000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
155413000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
128151000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
50583000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
35698000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
104830000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92453000
us-gaap Depreciation
Depreciation
16100000
us-gaap Depreciation
Depreciation
12200000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q3 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
16209000
CY2022Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
18948000
CY2023Q3 ntra Accrued Charges For Outsourced Testing
AccruedChargesForOutsourcedTesting
10960000
CY2022Q4 ntra Accrued Charges For Outsourced Testing
AccruedChargesForOutsourcedTesting
17036000
CY2023Q3 ntra Accrued Testing And Laboratory Materials From Suppliers
AccruedTestingAndLaboratoryMaterialsFromSuppliers
19902000
CY2022Q4 ntra Accrued Testing And Laboratory Materials From Suppliers
AccruedTestingAndLaboratoryMaterialsFromSuppliers
13281000
CY2023Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
8752000
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
8943000
CY2023Q3 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
35822000
CY2022Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
36710000
CY2023Q3 ntra Accrued Shipping Charges
AccruedShippingCharges
1203000
CY2022Q4 ntra Accrued Shipping Charges
AccruedShippingCharges
485000
CY2023Q3 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
5715000
CY2022Q4 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
4319000
CY2023Q3 ntra Accrued Specimen Service Fees
AccruedSpecimenServiceFees
6865000
CY2022Q4 ntra Accrued Specimen Service Fees
AccruedSpecimenServiceFees
6631000
CY2023Q3 ntra Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
11056000
CY2022Q4 ntra Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
23301000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11038000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7639000
CY2023Q3 ntra Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
1617000
CY2022Q4 ntra Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
1821000
CY2023Q3 ntra Accrued Interest
AccruedInterest
2695000
CY2022Q4 ntra Accrued Interest
AccruedInterest
1078000
CY2023Q3 ntra Other Accrued Sundry Expenses Current
OtherAccruedSundryExpensesCurrent
1906000
CY2022Q4 ntra Other Accrued Sundry Expenses Current
OtherAccruedSundryExpensesCurrent
4022000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
133740000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
144214000
CY2022Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
18948000
CY2021Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
17210000
ntra Insurance Carrier Reserves Additions
InsuranceCarrierReservesAdditions
7348000
ntra Insurance Carrier Reserves Additions
InsuranceCarrierReservesAdditions
15665000
ntra Insurance Refunds To Carriers
InsuranceRefundsToCarriers
1236000
ntra Insurance Refunds To Carriers
InsuranceRefundsToCarriers
990000
ntra Insurance Carrier Reserves Released
InsuranceCarrierReservesReleased
8851000
ntra Insurance Carrier Reserves Released
InsuranceCarrierReservesReleased
13947000
CY2023Q3 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
16209000
CY2022Q3 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
17938000
ntra Noncash Operating Activities Related To Right Of Use Assets
NoncashOperatingActivitiesRelatedToRightOfUseAssets
100000
ntra Noncash Operating Activities Related To Right Of Use Assets
NoncashOperatingActivitiesRelatedToRightOfUseAssets
22100000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11038000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7639000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
68287000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
76577000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
79325000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
84216000
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0667
CY2023Q3 us-gaap Lease Cost
LeaseCost
3600000
CY2022Q3 us-gaap Lease Cost
LeaseCost
3500000
us-gaap Lease Cost
LeaseCost
11000000.0
us-gaap Lease Cost
LeaseCost
10000000.0
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
3200000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1700000
us-gaap Operating Lease Payments
OperatingLeasePayments
8400000
us-gaap Operating Lease Payments
OperatingLeasePayments
7200000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3983000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
16031000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
16383000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
16732000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
13676000
CY2023Q3 ntra Lessee Operating Lease Liability Payments Due Year Five And After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
34000000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
100805000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
21480000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
79325000
CY2023Q3 us-gaap Purchase Obligation
PurchaseObligation
64642000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.6823
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7007
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5591
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.6230
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0341
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0418
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0162
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0315
CY2022Q4 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
30000000.0
CY2022Q4 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
100000000.0
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
80000000.0
CY2023Q3 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
20000000.0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
202000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
185000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
80000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
557000
CY2023Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22571000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20672000

Files In Submission

Name View Source Status
ntra-20230930_lab.xml Edgar Link unprocessable
0001558370-23-018379-index-headers.html Edgar Link pending
0001558370-23-018379-index.html Edgar Link pending
0001558370-23-018379.txt Edgar Link pending
0001558370-23-018379-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ntra-20230930.xsd Edgar Link pending
ntra-20230930x10q.htm Edgar Link pending
ntra-20230930xex31d1.htm Edgar Link pending
ntra-20230930xex31d2.htm Edgar Link pending
ntra-20230930xex32d1.htm Edgar Link pending
ntra-20230930xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
ntra-20230930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ntra-20230930_def.xml Edgar Link unprocessable
ntra-20230930_pre.xml Edgar Link unprocessable
ntra-20230930x10q_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending